Acute Coronary Syndrome News and Research RSS Feed - Acute Coronary Syndrome News and Research

St. Luke’s Emergency and Transport Services recognized for excellence

St. Luke’s Emergency and Transport Services recognized for excellence

St. Luke’s Emergency and Transport Services has received the American Heart Association’s Mission: Lifeline® EMS Silver Award for implementing quality improvement measures for the treatment of patients who experience severe heart attacks. [More]
Ticagrelor drug shows minor added benefit for patients with history of myocardial infarction

Ticagrelor drug shows minor added benefit for patients with history of myocardial infarction

The German Institute for Quality and Efficiency in Health Care assessed the added benefit of ticagrelor for patients with acute coronary syndrome already in 2011 in its very first dossier assessment, just after the Act on the Reform of the Market for Medicinal Products had come into force. [More]
Mortality risk high among diabetes patients with prior CV events

Mortality risk high among diabetes patients with prior CV events

Patients with Type 2 diabetes and acute coronary syndromes have a substantially increased risk of death in the 18 months after hospital admission for subsequent major nonfatal cardiovascular events, US researchers report. [More]
Age no barrier to vorapaxar use in ACS

Age no barrier to vorapaxar use in ACS

The protease-activated receptor 1 inhibitor vorapaxar offers the same benefits to older and younger patients with non-ST segment elevation acute coronary syndromes, shows further analysis of the TRACER trial. [More]
Diabetes-heart disease combination can increase death risk

Diabetes-heart disease combination can increase death risk

The combination of type 2 diabetes and coronary artery disease can be deadly. New research from a global study led by a physician from UConn Health has found that patients with Type 2 diabetes admitted into the hospital for congestive heart failure face a one in four chance of dying over the next 18 months. [More]
Rapid hand-held troponin blood test for heart attack diagnosis launched by Philips

Rapid hand-held troponin blood test for heart attack diagnosis launched by Philips

Chest pain patients presenting at the emergency department are set to benefit from a major development by Royal Philips. The company today announced that it has CE marked its cardiac troponin I (cTnI) blood test on the Minicare I-20 handheld device. Minicare cTnI delivers its lab comparable test results in less than 10 minutes near the patient, reducing the time for the physician to decide on treatment. [More]
Pre-procedural use of antiplatelet therapy becoming less routine in heart attack treatment

Pre-procedural use of antiplatelet therapy becoming less routine in heart attack treatment

Doctors worried about dangerous blood clots in patients undergoing a coronary artery procedure— such as angioplasty to treat a heart attack — will often administer antiplatelet therapy to head off complications. [More]
SPRINT supports stringent BP goals for elderly

SPRINT supports stringent BP goals for elderly

Analysis of SPRINT participants older than 75 years shows that they too benefitted from an intensive blood pressure target of 120 mmHg. [More]
CMR 'may be preferable' to SPECT for CHD prognosis

CMR 'may be preferable' to SPECT for CHD prognosis

Long-term follow-up of the CE-MARC study suggests that cardiovascular magnetic resonance could be a better predictor of cardiovascular events than single-photon emission computed tomography in patients with coronary heart disease. [More]
Younger women more likely to experience one-year adverse cardiovascular events after PCI

Younger women more likely to experience one-year adverse cardiovascular events after PCI

Women younger than 55 years of age who undergo percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) are more likely to experience one-year adverse cardiovascular events due to risk factors such as diabetes and chronic kidney disease, yet they are less likely to receive potent antiplatelet therapy than men. The PROMETHEUS study found that outcomes for both men and women post-PCI are dependent on their baseline risk factors, not their sex. [More]
Diagnosing heart attacks in 1 hour: an interview with Dr Richard Body

Diagnosing heart attacks in 1 hour: an interview with Dr Richard Body

Cardiac troponin is a highly sensitive and specific biomarker for myocardial injury but concentrations in the blood rise over several hours after the onset of an acute myocardial infarction. [More]
Investigational drug provides no improved protection to patients with contrast-induced acute kidney injury

Investigational drug provides no improved protection to patients with contrast-induced acute kidney injury

Patients treated with CMX-2043--an investigational drug that has previously shown some ability to protect heart muscle from damage during stenting--saw no improved protection in their kidneys compared to placebo, according to research presented at the American College of Cardiology's 65th Annual Scientific Session. [More]
Cholesterol drug evacetrapib fails to reduce risk of cardiovascular events

Cholesterol drug evacetrapib fails to reduce risk of cardiovascular events

Despite lowering low-density lipoprotein (LDL), known as "bad" cholesterol, while markedly increasing levels of high-density lipoprotein (HDL), or "good" cholesterol, a large clinical trial to investigate the cholesterol drug evacetrapib was discontinued early after a preliminary analysis showed it did not reduce rates of major adverse cardiovascular events, according to research presented at the American College of Cardiology's 65th Annual Scientific Session. [More]
Routine stress adversely affects women’s heart

Routine stress adversely affects women’s heart

While the number of men dying from a heart attack has been constantly decreasing during the past twenty years, the fatal risk particularly in young women has increased significantly. Gender medicine has already demonstrated that women exhibit different symptoms. A new insight shows that stress in the daily routine has particularly adverse effects on the hearts of women. This was emphasised by Alexandra Kautzky-Willer, Professor for Gender Medicine of MedUni Vienna, on the occasion of the impending International Women's Day on 8 March 2016. [More]
Gender associated with risk of cardiovascular recurrence in adults

Gender associated with risk of cardiovascular recurrence in adults

Sex (biological and physiological characteristics) differences are increasingly being studied to assess symptoms, risk factors and outcomes for various diseases. Now, a new pan-Canadian study led by a team from the Research Institute of the McGill University Health Centre, suggests that gender rather than sex is associated with the risk of recurrence of cardiovascular events in adults. [More]
Cardiome files NDS with Health Canada's TPD for approval of intravenous vernakalant

Cardiome files NDS with Health Canada's TPD for approval of intravenous vernakalant

Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced the filing of a New Drug Submission (NDS) with Health Canada's Therapeutic Products Directorate (TPD) seeking Canadian approval of intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults with AF for up to 7 days. [More]
Johns Hopkins researchers present new healthcare tips from American Heart Association Meeting

Johns Hopkins researchers present new healthcare tips from American Heart Association Meeting

Linking digital activity trackers to smartphones and periodically pinging users with personalized texts that urge them to walk more can significantly increase physical activity levels and spark healthy behavior changes, according to findings of a pilot study conducted at Johns Hopkins. [More]
Infections experienced in childhood may lead to premature ACS or heart attacks

Infections experienced in childhood may lead to premature ACS or heart attacks

"Cardiovascular disease (CVD) is the number one killer worldwide, including in Indonesia where it accounts for 31.9% of all deaths," said Dr Qanitha. "CVD risk factors are rising rapidly in South-East Asia, particularly in young people. Most Indonesian CVD patients are under 56 years old and still economically productive. This very young CVD onset raises the question of whether local circumstances may play a role." [More]
Advanced targeted therapies dominate treatment pipeline for colorectal cancer, finds Frost & Sullivan

Advanced targeted therapies dominate treatment pipeline for colorectal cancer, finds Frost & Sullivan

A vast number and variety of remedies are steadily joining the treatment pipeline for colorectal cancer. High incidence of the disease, unmet clinical needs, and huge commercial potential are attracting drug developers to the market. [More]
Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen Pharmaceuticals, Inc., and its development partner, Bayer HealthCare, today announced results from PMSS (Post-Marketing Safety Surveillance) and XANTUS (XARELTO for Prevention of Stroke in Patients with Atrial Fibrillation), their landmark real-world studies evaluating the safety of XARELTO in people with non-valvular atrial fibrillation (NVAF). [More]
Advertisement
Advertisement